Bernhard Zelger
Innsbruck Medical University
65 Papers
1K Citations
Bernhard Zelger is an academic researcher from Innsbruck Medical University. The author has contributed to research in topics: Medicine & Dermatofibroma. The author has an hindex of 33, co-authored 65 publications. Previous affiliations of Bernhard Zelger include University of Innsbruck.
Chat about Author
Papers
Expression of Fas and Fas Ligand After Experimental Traumatic Brain Injury in the Rat
Ronny Beer,Franz Gerhard,Marion Schöpf,Markus Reindl,Bernhard Zelger,Erich Schmutzhard,Werner Poewe,A. Kampfl +7 more
TL;DR: Induction of Fas and FasL expression in the cortex after TBI in the rat is revealed and strategies aimed to repress posttraumatic Fas-and FasL-induced apoptosis may open new perspectives for the treatment of TBI.
133
Life history of cutaneous vascular lesions in Sneddon's syndrome.
TL;DR: Sneddon's syndrome is a potentially fatal arterio-occlusive disorder characterized by generalized livedo racemosa and cerebrovascular lesions and skin biopsies often fail to yield diagnostic arterial lesions.
108
Sneddon's syndrome: diagnosis by skin biopsy and MRI in 17 patients.
G. Stockhammer,Stephan Felber,Bernhard Zelger,Norbert Sepp,G. Birbamer,Peter O. Fritsch,Franz Aichner +6 more
TL;DR: In this paper, the authors evaluated clinical, laboratory, histological, and neuroradiological findings in a series of 17 patients to improve diagnostic criteria for Sneddon's syndrome, characterized by generalized livedo racemosa and cerebrovascular lesions.
103
Immunohistochemically demonstrated metallothionein expression in malignant melanoma.
Bernhard Zelger,Anton Hittmair,M. Schir,C. Öfner,Dietmar Öfner,Peter O. Fritsch,Werner Böcker,Bharat Jasani,Kurt Werner Schmid +8 more
TL;DR: These immunohistochemical results, based on routinely processed paraffin‐embedded tissue, suggest that metallothionein expression in malignant melanoma is significantly associated with progressive disease and might therefore be a useful prognostic indicator.
98
Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans.
TL;DR: Atrophic dermatofibroma and atrophic dermat ofibrosarcoma protuberans are delineated as distinct entities clearly distinguishable from each other by clinicopathologic criteria.
97